Major depressive disorder (MDD) is one of the leading causes of disability worldwide, with approximately 30% of patients developing treatment-resistant depression (TRD) that does not respond adequately to conventional antidepressant treatment. Although ketamine has emerged as a fast-acting antidepressant for TRD patients, its underlying biological mechanisms in the human brain are still poorly understood, limiting efforts to optimize and personalize treatment.
In a new study published in the journal molecular psychiatry On March 5, 2026, a research team led by Professor Takuya Takahashi from the Department of Physiology, Yokohama City University Graduate School of Medicine used an innovative positron emission tomography (PET) imaging technique to directly examine changes in the glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), a key protein involved in synaptic plasticity and glutamatergic signaling. Patients receiving ketamine. Professor Takahashi points out:Although ketamine has shown rapid antidepressant effects in patients with treatment-resistant depression, the molecular mechanism of ketamine in the human brain remains unclear. ”
This advance was made possible by the research team’s previously developed PET tracer (¹¹C)K-2, which enabled visualization of cell surface AMPARs in the living human brain. Although preclinical studies have long suggested that ketamine’s antidepressant effects depend on AMPAR activity, this study provides the first direct evidence supporting this mechanism in humans.
The study combined data from three registered clinical trials conducted in Japan and included 34 patients with TRD and 49 healthy control participants. Patients received ketamine or a placebo intravenously for two weeks, and PET imaging was performed before starting treatment and after the last infusion.
The results revealed that TRD patients exhibited widespread region-specific AMPAR density abnormalities compared to healthy participants. Notably, ketamine did not induce uniform changes throughout the brain. Instead, clinical improvement was associated with dynamic region-specific regulation of AMPARs. An increase in receptor density was observed in several cortical areas, whereas a decrease was detected in reward-related areas, particularly the habenula. These region-specific changes were strongly correlated with reductions in depressive symptoms.
”Antidepressant effects of ketamine in TRD patients are mediated by dynamic changes in AMPARs in the living human brain” explained Professor Takahashi.Using the new PET tracer (¹¹C)K-2, we were able to visualize how ketamine changes AMPAR distribution across specific brain regions and how these changes correlate with improvement in depressive symptoms.These findings provide direct human evidence linking molecular mechanisms previously identified in animal models to clinical antidepressant effects.
This finding not only advances mechanistic understanding but also has important clinical implications. AMPAR PET imaging may be a valuable biomarker to assess and predict an individual’s response to ketamine treatment in TRD. Given the significant proportion of patients who do not respond to standard antidepressants, the identification of such biomarkers would address a significant unmet need in mental health care.
This study bridges the long-standing gap between preclinical research and clinical psychiatry by directly visualizing AMPAR dynamics in the living human brain. Our results establish AMPAR modulation as a central molecular mechanism underlying the rapid antidepressant effects of ketamine and highlight AMPAR PET imaging as a promising tool to guide personalized treatment strategies. Ultimately, this research may accelerate the development of more precisely targeted therapies for patients with treatment-resistant depression.
sauce:
Reference magazines:
Nakajima, W., others. (2026). AMPA receptor dynamics underlie the efficacy of ketamine in patients with treatment-resistant depression. molecular psychiatry. DOI: 10.0.4.14/s41380-026-03510-w. https://www.nature.com/articles/s41380-026-03510-w
